Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma

Invest New Drugs. 1998;16(1):93-6. doi: 10.1023/a:1006087114621.


Purpose: Pyrazoloacridine (PZA) is an acridine derivative selected for clinical development because of broad pre-clinical antitumor activity and solid tumor selectivity. Phase I evaluations with PZA have demonstrated predictable toxicity and suggested clinical efficacy. A phase II trial in patients with previously untreated advanced pancreatic cancer was conducted.

Methods: PZA was administered at a dose of 750 mg/m2 intravenously over 3 hours every 21 days. Seventeen patients were treated receiving a total of 46 courses of PZA.

Results: Of the 15 patients evaluable for response, no responses were observed (0% response rate, 95% confidence interval 0-22%). Major toxicities directly attributable to PZA included moderate neutropenia and mild neurotoxicity.

Conclusion: PZA at this dose and schedule of administration was inactive in patients with pancreatic carcinoma.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acridines / adverse effects
  • Acridines / therapeutic use*
  • Adenocarcinoma / drug therapy*
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Female
  • Humans
  • Leukopenia / chemically induced
  • Male
  • Middle Aged
  • Neutropenia / chemically induced
  • Pancreatic Neoplasms / drug therapy*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Thrombocytopenia / chemically induced
  • Treatment Outcome


  • Acridines
  • Antineoplastic Agents
  • Pyrazoles
  • NSC 366140